Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP-DM Trial
NCT06729996Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diabetes mellitus (DM) comparing Pioglitazone (PIO) with Empagliflozin (EMPA) (2 arms). Primary endpoints: Hemoglobin A1c at 24 weeks, Area under curve for glucose at 24 weeks and 3 more. Started May 2025; status: recruiting.
02
Drugs
pioglitazoneempagliflozin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT06729996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06729996.